drugset / Trial / NCT06061471
To Evaluate the Efficacy and Safety of AK111 Injection in the Treatment of Moderate to Severe Plaque Psoriasis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a randomized, double-blind phase II clinical study to evaluate the efficacy and safety of AK111 in the treatment of subjects with moderate to severe plaque psoriasis.
Timeline
- Start
- 2023-09-22
- Primary completion
- 2024-12-11
- Completion
- 2024-12-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GUMOKIMAB | Monoclonal antibody | — | Subcutaneous |